Clincosm LogoSign in Get a demo

The Disease Severity In Patients With Psoriasis

Sponsor
Universitas Sebelas Maret (Other)
Overall Status
Completed
CT.gov ID
NCT05943405
Collaborator
(none)
33
Enrollment
1
Location
7
Actual Duration (Months)
4.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This observational study aims to evaluate new markers to predict disease activity in psoriasis. The main question is SGOT, SGPT, GGT, hs-CRP, and apo B related to disease severity in psoriasis.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Psoriasis patients who had signed an informed consent were assessed for PASI scores and 5 cc of blood was drawn for GGT, hs-CRP, and apo B examinations. A PASI score is a tool used to measure the severity and extent of psoriasis. PASI is an acronym for Psoriasis Area and Severity Index.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    33 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Cross-Sectional
    Official Title:
    The Disease Severity In Patients With Psoriasis
    Actual Study Start Date :
    Jun 1, 2022
    Actual Primary Completion Date :
    Dec 30, 2022
    Actual Study Completion Date :
    Dec 30, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Gamma-Glutamyl Transferase [only in admission]

      Gamma-Glutamyl Transferase was check in admission, reference range for adults is 5 to 40 U/L (units per liter)

    2. Apolipoprotein B [only in admission]

      Apolipoprotein B (ApoB) is the primary apolipoprotein and is the carrier for the following lipids: chylomicrons, low-density lipoprotein ( LDL), very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and lipoprotein. Unit used in mg/dL

    3. High-sensitivity c-reactive protein [only in admission]

      High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation that predicts incident myocardial infarction, stroke, peripheral arterial disease, and sudden cardiac death. Unit used in mg/L

    4. PASI [only in admission]

      A PASI (The Psoriasis Area and Severity Index) score can range from 0 to 72

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Clinical diagnosis of Psoriasis
    Exclusion Criteria:

    • Heart Failure

    • Diabetes Mellitus

    • Kidney Disease

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Universitas Sebelas Maret Hospital Sukoharjo Central Java Indonesia 57161

    Sponsors and Collaborators

    • Universitas Sebelas Maret

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Nurhasan Agung Prabowo, MD, Head of Hospital Research Unit, Universitas Sebelas Maret
    ClinicalTrials.gov Identifier:
    NCT05943405
    Other Study ID Numbers:
    • NAP07
    First Posted:
    Jul 13, 2023
    Last Update Posted:
    Jul 13, 2023
    Last Verified:
    Jul 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Nurhasan Agung Prabowo, MD, Head of Hospital Research Unit, Universitas Sebelas Maret
    Psoriasis
    Psoriasis Area and Severity Index
    Gamma-Glutamyl Transferase
    CRP
    Apolipoprotein B
    Additional relevant MeSH terms:
    Psoriasis

    Study Results

    No Results Posted as of Jul 13, 2023